Shanghai Allist Pharmaceuticals Co. Ltd. A (688578.SS) stock: key figures, P/E, revenue and dividend

Health Care · Biotechnology · China · ISIN CNE100005XJ7

Price
84.13 CNY
Market cap
37.84 bn CNY
P/E (2025)
17.35
P/S (2025)
7.32
Dividend yield
1.43 %
Net margin
42.18 %
Return on equity (ROE)
–
Return on assets (ROA)
27.59 %

Shanghai Allist Pharmaceuticals Co. Ltd. A financials

Fiscal year20242025
Revenue3.56 bn CNY5.17 bn CNY
Gross profit3.39 bn CNY5.17 bn CNY
Operating income1.63 bn CNY2.57 bn CNY
EBIT1.62 bn CNY2.53 bn CNY
Net income1.43 bn CNY2.18 bn CNY
Diluted EPS – continuing operations3.18 CNY4.85 CNY

Full history since 2017, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

Sign up for freeOpen interactive view

About Shanghai Allist Pharmaceuticals Co. Ltd. A

Shanghai Allist Pharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research and development of tumor-targeted drugs in China in internationally. The company's lead product is vometinib mesylate tablet for the treatment of patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer (NSCLC). It also develops pralatinib capsules, as well as glerexyl citrate tablets for treating adult patients with locally advanced or metastatic NSCLC. The company was founded in 2004 and is based in Shanghai, China.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 21.10.2026. Details in the risk notice.

Shanghai Allist Pharmaceuticals Co. Ltd. A stock (688578.SS): P/E, revenue, dividend | finmetric